Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anavex does not have in house research. Anavex 3-71 was known as AF-710b and was developed in Dr. Fisher's lab at IIBR (Israel Inst for Biol Res). His lab specializes in muscarinic pharmacology. Anavex licensed it in 2014 from the commercial arm of IIBR (Life Science Research Israel). To my knowledge, the terms have never been published. There are two articles you can link to in Pubmed about its benefit in AD models.
Effective communication helps investors make informed investment decisions and enhances the transparency of public companies. On the other hand, a lack of clear and accurate communication (think Anavex) can lead to misunderstandings and mistrust, damaging the relationship between investors and companies.
Investors rely on various forms of communication to gather information about potential investment opportunities and assess the performance of existing investments. Companies are required to disclose regular financial statements, earnings reports, and other relevant information, to ensure that the public has access to accurate and up-to-date information about their operations and financial performance.
In addition to formal disclosures, public companies also engage in various forms of direct communication with investors so long as they do not disclose material, non-disclosed developments. These direct communications include one-on-one and group conference calls, roadshows, investor presentations and social media, which provide investors with an opportunity to ask questions and obtain more detailed information about a company's strategy, operations, and financial results. Done well, these interactions help to build trusting relationships between companies and investors and foster a greater understanding of each other's perspectives and priorities.
In conclusion, effective communication between investors and public companies is essential. Companies must be transparent and responsive to investor inquiries, while also utilizing technology to reach a wider audience. Investors, in turn, must take responsibility for seeking out accurate and relevant information and engaging with companies in a constructive and informed manner. By working together, companies and investors can build strong, mutually beneficial relationships that contribute to growth and a premium stock valuation.
Only a projected 350% increase over todays price.
Maybe I should buy some crypto instead.
Simple Notes from Conference Call:
- Fragile X trial to take place in USA; talks with FDA recently conducted.
- Dr. Missling is keen to get data off to the FDA and EMA (European regulators mentioned a few times). I discuss this with Dr. Grimmer.
- Strong language indicating cross-CNS platform. I discuss this with Dr. Grimmer.
- Rett Syndrome Burden of Illness presentation mentioned for the first time in a long time - indicates the company will tie patient improvement to parent/caregiver greatest concerns.
- Dr. Missling mentions brain atrophy - as we know, Lecanemab patients saw SIGNIFICANT brain atrophy, especially in the hippocampus. Looking forward to this data and hopefully some comparative charts.
- Reaffirms S1R as important to patient efficacy. I discuss S1R as a biomarker with Dr. Grimmer.
- Very much so looking forward to PDD OLE. I discuss PDD briefly with Dr. Grimmer.
The Faculty Here Are Failing. Market Truth Prevails.
Anavex had an online event before the market opened today, and then the share price went up 5.71% for the day. How could that have happened? All through the day, as every day previous, there were abundant postings on this board from real experts telling the frequent and many defects in Anavex science, clinical trials, and corporate leadership.
Only two explanations for this discrepancy; the Anavex is bad vs. Anavex has a future dichotomy.
The experts purveying their Anavex negatives, good people that they are, are simply not very good teachers. They are unable to clearly and simply convey the authentic deep truths of Anavex failures. They are sadly ineffective in conveying the truth. It’s there, but too detailed or complicated for general stock investor audiences to comprehend from our incompetent teachers.
Or, the investor audiences who come here to learn about Anavex, from what they’ve learned, now believe that Anavex actually has a future. Hence, shares were purchased and the AVXL price went up nicely today.
The naysaying faculty in this on-going “Introduction to Anavex Life Sciences Corp” course are going to have to do a better job. So far, they have presumed that their students are fellow faculty members and should understand, agree, and apply what they teach without question. Sorry. That’s not working right now, is it?
Of course the only truth that really counts is the truth of the current equity share price. Everything mentioned above is peripheral. What the inanimate “market” declares as the share price is the ultimate truth. Today’s real truth delighted most who visit this message board. They are glad that tuition rates are so low.
AVXL stock trading volume exceeded 2 million shared traded TODAY 7 February 2023.
Good luck and GOD bless,
The Cantor Price target also needs to be put into context that the contract was drawn up in 2018 at below $5. Sometimes 100% targets get met... They will be back in another financing round someday in the far future and the "Strong Buy" will be right back on.
Some ancient history for you:
https://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/s111267_8k.htm
Very interesting that during the CC that foreign countries drug regulators could be focusing on Anavex and possible approval of Anavex drugs and, Anavec very aware of this ... and the possibility that our FDA would need to play catch-up ... especially, with our desperate FDA approving a new Alzheimers drug causing that causes brains to bleed and patients to die.
Not bad. I bonds also look attractive, just not as much as last May when the rate was over 9%
Anavex Life Sciences Stock Shows Improved Price Strength Rating
https://www.investors.com/news/technology/anavex-life-sciences-stock-hows-improved-price-strength-rating/?src=A00220
Last Post.........lol
Super strong close.......nice conviction volume!
Pretty impressed with this close and intra-day trading action......
Hope Charlie Duncan would increase his target, but he probably won't...
Well, at least on analyst has hit his target. close at $11.75 today. Now that his target has been exceeded what will his next price target be? Up or down?
AVXL stock price up 5.76% today!!!
GOD bless,
not looking good for shorty humm.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
He's the best analyst, an old pro....and I know not easy to impress, so that will be not liked by many......check his record!
Nice comeback, but very impressed with the $XBI and $IBB on where they turned!
We need to see a strong pop over $12 now to meet my target....great volume!
I just got 5% on 11 month FDIC CD @5%.
May not appeal to WGT, but as part of a portfolio?
Up up and away for AVXL stock.
Good luck and GOD bless,
Powell's comments clearly impacted the valuation of nearly every stock index...for about 1/2 hour or so
Looks like Missling's comments must be the reason why AVXL is currently up 3.5% for the day and has added about $32M to its valuation, right? I mean, what else could today's increase be attributed to?
Yea cause Powell's comments impact the valuation of a tiny biotech company.
He decided to leave AVXL and be on sidelines. I don't think his reasons for leaving have changed == so, he'll likely remain on sidelines, imo.
Yea cause Powell's comments impact the valuation of a tiny biotech company.
crazy day but all loongs still in a very good hand.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
Back in early December 2022, Cantor Fitzgerald's Charles Duncan downgraded AVXL from Overweight to Neutral and lowered his price target down from $16.00 to $11.00. I wonder if he will be making any revisions in the near future...
Jerome Powell could be replaced as Chairman of the Federal Reserve for being too conservative with regarding to raising interest rates to tame inflation that is already under control. He should eat ch the money supply.
interest rates affect the stock market and the stock market movement affects AVXL's stock price.
GOD bless,
I am sure that the 2b/3 trial has yielded some complexities. The tipoffs are the combined dose arms (titration/dropout issues?) and the unusual endpoint measurements (to handle nonstandard response curves?). Additionally, Missling has previously noted the genomic study will be used for context, and this morning produced an interesting list of other AD symptoms to be analyzed. So, even as a Phase 3 this is complicated.
You can’t possibly know that without seeing the analyst’s earnings model and the assumptions he uses.
They make stuff up. Sound familiar?
$58 is a very good near term price target from Jones Trading,
GOD bless,
Yep
Latest Buy rating with lower price:
https://www.tipranks.com/news/blurbs/anavex-life-sciences-avxl-gets-a-buy-from-jonestrading-2
Earlier rating with $80 price
https://markets.businessinsider.com/news/stocks/anavex-life-sciences-avxl-receives-a-buy-from-jonestrading-1031949314
I wonder if people realize that not once in all these years has any analyst’s price target on AVXL been hit. Not even close.
The analysts are desperate to bring investment banking business into their firms, especially at a time when the investment banks are struggling.
“See how may times he said as soon as possible just to answer one simple question, guy don't understand anything about time and it's value.”
I haven’t done so yet but I’m planning on doing so as soon as possible. I’ll be soon, very soon. I promise.
He raised his price target to $80 back in early December 2022. Where did you see $58?
In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $58.00.
I guess you were taking a nap between 1:00pm EST - 1:30pm EST...
Umm the S&P and Nasdaq are positive and the DOW is headed there after Powell spoke??
Bourbon--" Soumit Roy from JonesTrading"--good find--analyst must have liked what he heard at the CC today !! Great !
CEO is not all that matters about a company’s fortunes. However terrible CM may be wrt communications, AVXL can still go anywhere depending on the science results.
Here is the list of outcomes that have to analyzed, some of which will require a lot of lab time before analysis.
Primary Outcome Measures :
ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition) [ Time Frame: 48 weeks ]
Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)
ADCS-ADL (Activities of Daily Living) [ Time Frame: 48 weeks ]
Reduction in decline of the ability to perform daily activities assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Activities of Daily Living Scale (ADCS-ADL)
Secondary Outcome Measures :
CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) [ Time Frame: 48 weeks ]
Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 48 weeks ]
Assess the safety and tolerability of ANAVEX2-73 compared to placebo
Other Outcome Measures:
Number of participants with change of brain volume assessed by MRI [ Time Frame: 48 weeks ]
To evaluate the effect of ANAVEX2-73 on structural and Arterial Spin Labeling (ASL) MRI scan assessments characteristic for AD pathophysiology compared to placebo over a 48-week treatment duration
Blood assessment [ Time Frame: 48 weeks ]
Blood assessment from baseline and compared to placebo at +48 weeks: Abeta40, Abeta42, T-tau, NFL, YKL-40, BACE1 concentration
CSF assessment [ Time Frame: 48 weeks ]
Changes in CSF parameters (Abeta40, Abeta42, T-tau, P-tau, NFL, YKL-40, neurogranin, BACE1 concentration) characteristic for AD pathophysiology from baseline and compared to placebo at
+48 weekstreatment differences within subgroups will be performed
Number of participants with pre-specified genetic variants [ Time Frame: 48 weeks ]
AD relevant pre-specified genetic variants will be assessed. Statistical testing of treatment differences within subgroups will be performed
RSCAQ sleep score [ Time Frame: Weeks 0, 4, 12, 24, 36, and 48 ]
To evaluate whether ANAVEX2-73 improves sleep continuity as assessed on a serial basis (weeks 0, 4, 12, 24, 36, and 48) with a questionnaire that assess reported sleep continuity (RSCAQ)
Oh go ahead and sell it all. Be safe. Why take a chance on a " liar/truth-hider".
Dang. This whole get rich quick thing is taking years. You'd think TGD would want to be more like a Hare for us shareholders. Why the Tortoise moves? It's like he's methodological or something.
LOL.............
In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $58.00.
Agreed. I believe we are now in an uptrend --vs-- last year where we were in a downtrend.
In the past we often saw a sell off after these events. Unfulfilled expectations.
Today is different.
I have...several times.
Not today, unfortunately. But in the past few years I have sold and bought back at a lower price. Got caught with my pants down a couple of times (where I bet the wrong way) so you have to be very careful.
The MMs almost always have the upper hand. They're the experts.
So why not sell and make more
Money if you are sure that’s what it is?
Umm the S&P and Nasdaq are positive and the DOW is headed there after Powell spoke??
all we need is ONE GOOD WIN
problem is Missling is like the Pittburgh Steelers offense, moves the ball down the field well but cant get it into the end zone.
Those two things are the same.
That makes sense for p2 trials, not p3;
there are large gaps between test completion and full readout because Anavex is both conducting clinical trials and wide-ranging, groundbreaking scientific research.
Remember for alz we had a p2a trial that was supposed to work all that out, with the P2b/3 trial for confirmation of efficacy and dose.
Ditto for PD, that was a fishing expedition so of course a long time to analyze is reasonable.
But the current alz results are targeted, and should not take that long.
At least throw us a bone and put out the 50mg top line results.
Nah. Just the MMs shaking the tree for weak hands.
They move it up quickly and get everyone excited, then take it down and hope that the weak hands sell off. Wash and repeat until you've sold all of your shares to them.
Then they take it higher next month.
Are you proposing a new drinking game?
See how may times he said as soon as possible just to answer one simple question ...?
Maybe look at fb group.. see if they had a statistic chart hit..
Followers
|
1067
|
Posters
|
|
Posts (Today)
|
16
|
Posts (Total)
|
461374
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |